November 1, 2017 Fed. Circ. Clarifies Law For Functional Antibody Claims
October 25, 2017 The Supreme Court’s interpretation of the biosimilars statute and the value of certainty
October 5, 2017 A New Strain Of Inequitable Conduct Litigation
June 15, 2017 High Court Interprets The Biosimilars Statute — What Now?
June 6, 2017 Update on Biosimilar Approvals and Pending Applications in Europe and the U.S.
April 27, 2016 A Breakthrough Technology is Caught in an Epic Patent Battle
March 16, 2016 Biosimilar Makers Turn To IPRs Despite Mixed Results
December 9, 2015 All Camps Agree: Memorable Biosimilar Names are a Must
October 27, 2015 TPP Biologics Exclusivity Period Maintains The Status Quo
June 2015 Biobetters: The Advantages and Challenges of Being Better
June 2015 New Targets in the Crosshairs: A forum to invalidate patents is now being used on biotech firms
April 2015 The Value of Being Highly Similar: First U.S. Biosimilar
October 2014 If High Court Reverses Teva, Litigation Costs May Increase
February 2012 FDA Issues Draft Guidelines for Biosimilars
June 2011 Supreme Court Decision: Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc.